FDA Issues Draft Guidance Regarding the Use of Data from Foreign Clinical Studies

The FDA recently issued a draft document clarifying when medical device manufacturers can rely upon clinical data from studies outside of the United States to support their domestic regulatory submissions. In it, the FDA generally recognized that foreign clinical data can be used so long as the data constitutes valid scientific evidence. Public comments are being accepted through July 20, 2015. [5/7/15]